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Age-related macular degeneration (AMD) is an ocular neurodegenerative disorder and is the leading cause of legal
blindness in Western societies, with a prevalence of up to 8 % over the age of 60, which continues to increase with
age. AMD is characterized by the progressive breakdown of the macula (the central region of the retina), resulting
in the loss of central vision including visual acuity. While its molecular etiology remains unclear, advances in
genetics and genomics have illuminated the genetic architecture of the disease and have generated attractive
pathomechanistic hypotheses. Here, we review the genetic architecture of AMD, considering the contribution of
both common and rare alleles to susceptibility, and we explore the possible mechanistic links between
photoreceptor degeneration and the alternative complement pathway, a cascade that has emerged as the most
potent genetic driver of this disorder.Background
Age-related macular degeneration is the third leading
cause of vision loss worldwide. It is a late-onset disease
with a complex etiology. Major risk factors contributing
to susceptibility include age, family history, and smoking
[1–3]. The earliest clinical manifestations of age-related
macular degeneration (AMD) are focal deposits of debris,
termed drusen, which are also considered to be a normal
part of aging, present almost ubiquitously in the eyes of
healthy individuals over the age of 50. Progression into the
spectrum of pathological consequences begins with exces-
sive accumulation of drusen in the central retina during
the early/intermediate stages of AMD, followed by local-
ized inflammation, and ultimately neurodegeneration in
the macula that characterizes advanced stages of AMD.
Combining epidemiological and genetic approaches
has enabled the identification of environmental and gen-
etic contributors to AMD, both of which have tracked
with technological advances in conceptual and practical
statistical and genomic tools. Linkage of an AMD locus* Correspondence: Nicholas.Katsanis@duke.edu
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(http://creativecommons.org/publicdomain/zeto 1q32 [4, 5], and the genome-wide association at the
complement factor H (CFH) locus [6] led to the identifi-
cation of the first common genome-wide significant risk
variant, Y402H, that has upon sequencing in ethnic
stratified cohorts revealed differential frequencies ran-
ging from 5 % in East Asian populations to 35 % in
European populations [7, 8]. This discovery propagated
numerous genetics and genomic studies that have contrib-
uted to our understanding of the pathomechanisms con-
tributing to AMD. Notably, the subsequent association of
common and rare alleles at or near several additional
complement genes (CFH, C2/CFB, C3, CFI, and C9) has
had a significant impact of the formation of pathomecha-
nistic hypotheses, with the cumulative evidence both from
human genetics but also from histopathological studies
highlighting a major role of the alternative complement
pathway as a driver of AMD [9–21]. Here, we synthesize
genetic evidence from rare- and common-allele studies in
AMD, and we discuss the emergent picture of the genetic
architecture of this atypical complex trait. Moreover,
benefiting from the discovery of likely potent coding mu-
tations in genes encoding complement components, we
explore how these mutations might impede specific func-
tions and discuss the potential contribution of aspects of
this pathway to AMD pathogenesis.le is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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The retina is composed of five major layers: the neuro-
sensory retina; the retinal pigment epithelium (RPE);
Bruch’s membrane (BM); the choriocapillaris; and the
choroid (Fig. 1). The sensory cells of the neural retina
are the photoreceptors (rods and cones), which through
phototransduction convert light into electrical signals.
Adjacent to the photoreceptors is the RPE, a part of the
blood-ocular barrier and has numerous functions, in-
cluding photoreceptor outer segment phagocytosis;
regulation of the transportation nutrients; and cytokine
secretion [22]. Lining the basal side of the RPE is BM,
which is a pentalaminar extracellular matrix (ECM) con-
sisting of elastin semipermeable barrier between inner
and outer collagenous zones that provides connective
tissue-based structural support and transport of waste
from photoreceptors and RPE to the choroid and nutri-
ents from the choroid to the RPE. The outermost layer
of BM is composed of the basement membrane of the
choriocapillaris, a fenestrated capillary bed that together
with the choroid, a highly vascularized, pigmented tissue,
are responsible for supplying the high metabolic de-
mands of oxygen and nutrients to the outer retina [23].
During the natural process of aging, the human eye
undergoes physiological changes that include changes in
the distribution of photoreceptors (30 % loss of rod pho-
toreceptors [24]); thickening of BM [25]; and accumula-
tion of sub-RPE debris, including drusen [22, 26–29].
Drusen are composed of esterified cholesterol, phospho-
lipids, lipofuscin, inflammatory components (e.g., com-
plement), and other intra- and extraocular degenerative
materials [30, 31]. They are classified according to their
appearance, with inert, “hard” drusen being small with
well-demarcated borders in contrast to the generally
pathogenic “soft” drusen that lack distinct borders andFig. 1 Illustration of the anatomical retinal pathology associated with the v
central retina in normal and in AMD. As the disease progresses, Bruch’s me
drusen and retinal pigmented epithelium (RPE) pigment abnormalities. As
observed. In the two late forms of AMD (Dry and Wet), there is extensive d
choroid in the Dry form and choroidal neovascularization (CNV), hemorrhag
circuitry including the horizontal and bipolar cells remains intact initially. Th
Art (http://www.servier.com/Powerpoint-image-bank)can range in size from <63 to >124 μm in diameter, the
larger diameters coinciding with disease progression [32].
The clinical pathology of AMD has been described ex-
tensively [3, 33]. It involves the progressive degeneration
of the macula, a small, pigmented area at the center of
the retina that has the densest concentration of photore-
ceptors and is responsible for visual acuity. Damage to
the macula results in loss of central vision. Initial indica-
tions of AMD are seen as focal hyperpigmentation of
the RPE and accumulation of sub-RPE deposits, includ-
ing drusen, both between BM and the RPE and within
the RPE itself [34, 35].
Even though the degeneration of rods and cones does
define the end-stage of the disorder, AMD is not a pri-
mary disease of the photoreceptor; most of the candidate
processes, biochemical pathways, and molecules exert
their effects primarily on the RPE-choroid complex [36].
AMD subtypes
The anatomical histopathology and clinical progres-
sion contribute to the clinical definition of four major
AMD subtypes as categorized by the Age-Related Eye
Disease Study (AREDS) severity scale grading system
[37]: 1. Early AMD; 2. Intermediate AMD; 3. Ad-
vanced non-neovascular (“Dry” or geographic atrophy)
AMD; and 4. Advanced neovascular (“Wet” or exuda-
tive) AMD [32, 38, 39]. Early AMD features few small
(<63 μm) or medium-sized drusen (63–124 μm) and pig-
mentary abnormalities in the RPE, resulting in either mild
visual impairment (blurred vision or decreased contrast
sensitivity) or can be asymptomatic. The progression from
early to intermediate AMD is hallmarked by the appear-
ance of at least one large druse (>125 μm), along with nu-
merous medium-size drusen. This pathology can progress
to one of the two advanced forms of AMD: Dry AMDarious AMD subtypes. Diagram of the outer layers of the human
mbrane (BM) increases in thickness. Early AMD is associated with small
the disease progresses to the intermediate form, additional drusen are
rusen and photoreceptor cell death, with atrophy of the RPE and
ing, and RPE detachment in the Wet form. In all forms, the underlying
is figure was prepared using Servier Medical
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and atrophy of the RPE and choroid; or Wet AMD
(neovascular), defined by newly formed vessels (chor-
oidal neovascular membranes (CNV)) and RPE de-
tachment. While occurring gradually in the Dry form
versus suddenly/profoundly in the Wet form, the end
result of both of these processes leads to photorecep-
tor cell death and vision loss (Fig. 1, Table 1).
Genetics of AMD: common variants versus rare
variants
AMD exemplifies complex disorders: natural history and
epidemiological studies have highlighted a prominent
environmental role in disease risk with factors such as
smoking resulting in a relative risk (RR) of >2, diet and
obesity (RR > 2), nutritional supplements (odds ratio
(OR) ~0.6) all contributing to pathogenicity [40]. In
addition, family- and population-based studies have also
highlighted that AMD carries a significant genetic bur-
den, demonstrating >45 % concordance found in mono-
zygotic and dizygotic twins as well as a recurrence-risk
ratio between three to six times greater in siblings than
in the general population [41–46].
In many ways, the dissection of the genetic basis of
AMD has been an early beneficiary of advances in gen-
etic and genomic technologies, wherein the development
of both analytic platforms (genotyping, sequencing) as
well as statistical methods, have found early application
in this field.
Before our ability to query the genome in toto, complex
trait studies focused on more traditional tools such as
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sensitivity) orthe latter, AMD was shown to be associated with two
genes, ABCA4 (ATP-binding cassette subfamily A mem-
ber 4) and APOE (apolipoprotein E), both of which only
confer a minor risk contribution to AMD. ABCA4 is a
causal gene for Stargardt disease, a retinopathy whose
clinical symptoms overlap with AMD [47, 48]; APOE is a
gene associated with Alzheimer’s disease (AD), a neuro-
logical degenerative disorder, whose pathology overlaps
with AMD [49]. Nonetheless, and despite this initial
discovery, the candidate gene approach was largely unsuc-
cessful in identifying genetic contributors to AMD. This
was due in part to limited cohort sizes, imperfect statis-
tical methodologies, and unclear pathomechanisms hin-
dering the ability to define candidate genes and in part
due to our lack of appreciation of the extensive rare and
common variation carried in human genomes [50–52].
In the era following the completion of the human gen-
ome project and the International HapMap Project,
traditional family-based studies retained utility, as exem-
plified by the family-based linkage mapping of an AMD
locus on 1q25-q31 and on 10q26 [4, 53]. However, trans-
formative genetic progress in AMD was driven by the
common-allele hypothesis explored through genome-
wide association studies (GWAS) [6, 54]. Remarkably,
modest GWAS analysis on 96 cases and 50 controls
yielded a genome-wide significant signal (P < 10−7) on
1q32 of a common single nucleotide polymorphism
(SNP) on a gene encoding CFH that revealed a poly-
morphism in linkage disequilibrium, Y402H, that has
proven to be a common, predisposing allele that confers
a two- to sevenfold increased risk for developing AMD
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modestly sized GWAS performed on 96 cases and 130
controls yielded a genome-wide significant signal on
10q26, another primary locus for AMD that contains the
candidate genes ARMS2/HTRA1 (age-related maculopa-
thy susceptibility 2/HtrA serine peptidase 1) coding for a
protein of unknown function and a serine protease, re-
spectively [54, 57]. Thereafter, additional GWAS studies
with progressively increasing cohort size led to the iden-
tification of more associated loci but generally resulted
in diminishing returns with many of the loci having a
minor contribution to AMD (Table 2).
The associated loci discovered also germinated tar-
geted sequencing strategies with a goal of identifying
rare variants that might (a) provide direct causal evi-
dence for the gene(s) in associated regions; (b) improve
our measure of the overall risk of such genes to AMD
pathogenesis; and (c) inform the direction of effect. Tar-
geted high-throughput sequencing in combination with
genotyping of the CFH locus led to the identification of
a highly penetrant, rare variant R1210C which was
shown to be associated with advanced AMD and to po-
tentially result in disease onset 6 years earlier [58]. Simi-
larly, in a smaller discovery cohort of 84 unrelated AMDTable 2 Past genome-wide association studies of AMD
Discovered gene/locus Method
CFH Affymetrix GeneChip Mapping 100K Set of m
HTRA1/LOC387715 Affymetrix GeneChip Mapping 100K Set of m
LIPC Affymetrix SNP 6.0 GeneChip and Sequenom
CETP Affymetrix SNP 6.0 GeneChip and Sequenom
TIMP3 Illumina Human370 Bead Chips and Illumina
II assay
SKIV2L Affymetrix SNP 5.0 GeneChip
MYRIP Affymetrix SNP 5.0 GeneChip
TNFRSF10A/LOC389641 Illumina Human610-Quad BeadChip and Illum
HumanHap550v3 BeadChip
FRK/COL10A1 Affymetrix SNP 6.0 GeneChip and Illumina
HumanCNV370v1 Bead Array
VEFGA Affymetrix SNP 6.0 GeneChip and Illumina
HumanCNV370v1 Bead Array
COL8A1/FILIP1L Meta-analysis of GWAS
APOE Meta-analysis of GWAS
IER3/DDR1 Meta-analysis of GWAS
SLC16A8 Meta-analysis of GWAS
TGFBR1 Meta-analysis of GWAS
RAD51B Meta-analysis of GWAS
ADAMTS9/MIR548A2 Meta-analysis of GWAS
B3GALTL Meta-analysis of GWAS
Meta-analysis genotyping method/platforms include Illumina HumanHap300, Hum
250K Nspl, Illumina Human670-QuadCustom chip, Illumina 660-Quadv1A, Illumina
Hap550v3 BeadChip, Illumina Infinium II HumanHap550, Affymetrix GeneChip Hupatients, another penetrant, rare missense mutation in
complement factor I (CFI), was unveiled, encoding
G119R. This allele confers high risk to AMD (OR = 22.2),
with patients with the heterozygous mutation having
lower FI serum concentration [19].
With a goal of identifying elusive rare variants, a larger
targeted exon sequencing study was undertaken in 2013,
in which all exons of the 681 genes mapping at or close
to all the AMD reported loci were sequenced in 1676
cases, 745 controls, and 36 siblings with discordant dis-
ease status [59]. This study combined sequencing-based
genotypes, with the exome chip genome-wide genotyp-
ing data, with SNP genotyping to uncover K155Q (OR =
2.8) in the complement component C3 gene (C3) and
P167S (OR = 2.2) in C9 as contributors to AMD disease
pathophysiology. Importantly, the study also showed an
overall increase in the burden of rare variants in cases
compared to controls. Much of that signal originated
from specific genes, such as CFI (7.8 % in cases com-
pared to 2.3 % in controls). However, the data suggested
that there were variants in additional genes that were
likely involved but could not be powered sufficiently to
show association for specific alleles [59]. More recent
studies have involved a targeted capture enriched for# Cases/Controls OR Reference
icroarrays 96/50 4.6–7.4 [6]
icroarrays 99/131 1.66–11.14 [54]
979/1709 0.82 [124]
979/1709 1.15 [124]
Infinium 2157/1150 0.63 [125]
1896/1866 0.54 [126]
1896/1866 0.86 [126]











an610-Quad, HumanHapCNV370, or HumanCNV370v1 BeadChips, Affymetrix
610-Quad, Illumina Infinium HumanHap300K, HumanHap550v1, or Human-
man Mapping 250k Styl Array, Affymetrix 6.0 or 1M
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ment of rare variants in CFH in AMD patients [60] as
well as the largest AMD GWAS study to date that ex-
amined >12 million variants in 16,144 patients and
17,832 controls [61]. This study leads to the identifica-
tion of 52 common and rare variants across 34 loci, 16
of which reached genome-wide significance for the first
time [61]. Taken together, these studies highlight two
key points. First, they showed that, for AMD, a blend of
rare and common alleles can contribute substantially to
the disease burden and, as accepted by evolutionary the-
ory, coding alleles of major functional effect can have a
much larger contribution to susceptibility. Second, how-
ever, was the more sobering observation that AMD is
quite different from most other common traits studied
to date. A few exceptions notwithstanding, the genetic
architecture of AMD has intimated the presence of a
few genes in which common, modestly penetrant alleles
account for a significant fraction of the genetic burden,
with rare coding variants in the same genes providing
both causal evidence and adding further to the popula-
tion burden [6, 58, 62, 63]. When juxtaposed with the
>1000 GWAS executed for a variety of traits, this
landscape has, for the most part, been confined to
this disorder. The reason for this is unclear. These
observations might underscore a “winner’s curse” of
the first major complex trait’s GWAS successes. More
importantly, they raise the possibility that the bio-
chemical underpinnings of AMD might be fundamen-
tally different from other complex traits and that
understanding the reasons for such differences might
inform our approach to both genetic discovery and
therapeutic design.
Also contrasting other GWAS approaches in other
diseases, a significant fraction of the susceptibility sig-
nal in AMD has mapped to, or near, genes encoding
components of the complement cascade, although this
is not the sole pathway implicated. Overall, the genes
and alleles thought to confer significant susceptibility
to AMD pathology can be clustered broadly into five
major pathways (Table 3): (a) the inflammation and
immune response, (b) lipid metabolism and transport,
(c) extracellular matrix and cell adhesion, (d) angio-
genesis, and (e) cellular stress responses. Among
these, risk assessment analysis for either common or
rare alleles has highlighted in genes encoding comple-
ment pathway components. The common variants
near six complement genes, CFH, C2/CFB, C3, CFI,
and C9 together, account for almost 60 % of the
AMD genetic risk [36]. Notably, for the rare alleles
found in sufficient recurrent rates to empower mean-
ingful studies, the individual risk to AMD is sharply
higher and appears as if they are almost Mendelian,
as observed in the case of CFI [19].A pathogenic route to AMD: alternative
complement pathway
One of the leading candidates for predisposition to
AMD is the inflammatory pathogenesis theory, which
hypothesizes dysregulation of the immune response, spe-
cifically complement system [6, 9, 12, 14, 15, 20, 55, 56,
64–68]. Reports dating back to 1875 have hypothesized
that macular lesions were due to inflammation and that
disciform degeneration were associated with choroidal
inflammation [69]. Since then multiple components of
the complement pathway have been linked to AMD and
its pathological consequences [15, 16, 30, 64, 70, 71].
The complement system is a specialized part of innate
immunity that can respond to antigen-antibody com-
plexes (classical pathway) or bacterial mannose groups
(lectin pathway) and can also be active in a low-level
continuous state (alternative pathway (AP)), to allow for
an immediate amplified response [72]. All complement
pathways culminate in the creation of the membrane at-
tack complex (MAC) for cell lysis and organismal
defense.
AMD is not the first human genetic disorder associ-
ated with AP complement dysfunction. A number of dis-
orders are thought to be the result of excessive AP
activation, including membranoproliferative glomerulo-
nephritis type II (MPGN type II); atypical hemolytic
uremic syndrome (aHUS); and paroxysmal nocturnal
hemoglobinuria (PNH, a rare form of hemolytic anemia).
Of note, MPGN type II, which is characterized by renal
disease and low serum C3 levels, is also associated with
complete FH deficiency, arguing for a mechanistic simi-
larity between MPGN and AMD [55, 73]. Similarly,
aHUS has been associated with low FH levels in addition
to low C3 levels and has mutations in several AP com-
ponents, however, at a unique haplotype compared to
AMD and MPGN [73]. PNH is caused by mutations in
phosphatidylinositol glycan-complementation class A
(PIGA) that is essential in the establishment of glyco-
phosphatidylinositol anchors. Two known inhibitors of
AP activation are glycolipid-anchored proteins that are
required for the regulation at the C3 convertase step and
MAC assembly [74].
Dysregulation of the AP specifically is currently
thought to underlie AMD. Several lines of supporting
evidence include (1) the presence of complement com-
ponents in the choriocapillaris and the retina, especially
in drusen [14–16, 75]; (2) increased MAC in the chorio-
capillaris of AMD patients [18]; and (3) the genetic asso-
ciation of C2, C3, CFB, CFI, and the regulator of
complement activation (RCA) gene cluster on 1q32
(which includes CFH and CFHR1-5) with AMD [9–13,
17, 19–21]. However, the effects of variation within the
components of the AP on AMD pathogenicity is largely
unknown.
Table 3 Genes associated with AMD that cluster into five major pathways




complex, class I, C
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CX3CR1 Chemokine receptor 1 TLR4 Toll-like receptor 4
CFI Complement
factor I
TLR3 Toll-like receptor 3 CYP24A1 Cytochrome P450, family






















VTN Vitronectin GSTT1 Glutathione
S-transferase tau 1
TGFBR1 Transforming growth
factor, beta receptor 1
Lipid metabolism and transport Extracellular matrix and cell adhesion
ABCA1 ATP-binding cassette,









subfamily A, member 4
LIPC Hepatic lipase ARMS2 Age-related maculopathy
susceptibility 2
TIMP3 Tissue inhibitor of
metalloproteinase 3
APOE Apolipoprotein E LPL Lipoprotein lipases ADAMTS9 ADAM metallopeptidase
with trhombospondin















COL10A1 Collagen, type X, alpha 1 VTN Vitronectin
CYP24A1 Cytochrome P450,




CST3 Cystatin C ABCA7 ATP-binding cassette,
cubfamily A, member 7




CX3CR1 Chemokine receptor 1 ACTG1 Actin gamma 1
Angiogenesis F13B Coagulation factor XIII,
B polypeptide






FBLN5 Fibulin 5 COL4A4 Collagen, type IV, alpha 4
COL10A1 Collagen, type X,
alpha 1
MMP9 Matrix metallopeptidase 9 HMCN1 Hemicentin ITGA7 Integrin, alpha 7




HTRA1 HtrA serine peptidase 1 MYL2 Myosin, light chain 2,
regulatory, cardiac, slow
CST3 Cystatin C SERPINF1 Serpin peptidase
inhibitor, clade F
MMP9 Matrix metallopeptidase 1
FBLN5 Fibulin 5 TIMP3 Tissue inhibitor of
metalloproteinase 3
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pathway components
Low levels of constitutive complement activation via the
AP allows for immediate immune response. It involves
the central molecule of all three arms of the comple-
ment pathway, C3. In the AP, C3, is activated in two
ways (Fig. 2): (1) it is either cleaved by convertases/
plasma proteases to generate C3b or (2) a small portion
is hydrolyzed spontaneously to C3H2O establishing a
continuous “tick-over” ready for immediate C3b depos-
ition on pathogens for target opsonization [76–79]. Fac-
tor B (FB) binds to C3H2O or C3b and the complex is
cleaved by the plasma protease factor D (FD) forming
the essential C3 convertase (C3bBb or C3H2OBb), lead-
ing to an amplification loop that cleaves and assembles
C3 to C3b to C3bBb continuously. The accumulation of
C3b leads to C3b binding to C3bBb, thereby creating a
new enzyme, the C5 convertase (C3bBbC3b) that cleaves
C5 to C5a (an anaphylatoxin and chemoattractant) and
C5b, a component of the lytic pore which combines with
C6–C9 to form the membrane attack complex (MAC)
resulting in cell lysis [72].
The AP has the unique characteristic of being able to
be activated spontaneously, allowing for an immediate
immune response, which must be tightly regulated to
prevent excessive activation. Intrinsically, the AP has
two major negative regulators encoded by CFH and CFI.
CFH is the soluble inhibitor of the complement cascade
and encodes a secreted glycoprotein, FH that acts as co-
factor for FI mediated cleavage of C3b as well as acceler-
ating decay of the C3bBb convertase.
Many cells also express membrane-associated AP reg-
ulators that hinder the C3 amplification loop and/or pre-
vent the deposition/accumulation of C3b on self-tissue.
These membrane-associated proteins include membrane
cofactor protein (MCP), decay-accelerating factor (DAF),
and complement receptor 1 (CR1) all of which are
encoded by genes located within the RCA gene cluster
on 1q32 [80]. MCP and CR1 have cofactor activity for
CFI, while CR1 along with DAF have decay acceleration
activity. Differential expression of MCP has been linked
to AMD and upon the addition of an environmental
stimulus such as smoking, a risk factor of AMD, both
MCP and DAF are down regulated [81, 82]. Both activat-
ing and inhibiting components have been reported to
harbor variants that potentially have functional impactson the AP (Table 4), with an increase in overall muta-
tional burden being reported in CFH and CFI in AMD
patients [60, 83]. These perturbations of the components
themselves or of their ability to interact with other AP
components typically result in uncontrolled AP
activation.
Pathogenic outcomes of the AP
Advanced age is the only risk factor common to all
AMD patients. During the aging process, the physio-
logical changes include redistribution of the photorecep-
tors, thickening of BM, and accumulation of debris in
the eye in conjunction with environmental factors and
genetic variation contribute to cascading dysfunction of
physiological pathways such as lipid transport, angiogen-
esis, stress response, and ECM remodeling [24–26]. In
turn, disruption of each of these pathways can lead to an
inflammatory and an AP immune response ultimately
culminating in cell death [72]. Each of these pathways
has been hypothesized to alter components of the retina
[36, 84] affecting the interdependence of the photore-
ceptors, RPE, BM, and choriocapillaris making it chal-
lenging to understand the model for AMD pathogenesis.
During the early stages of AMD, sub-RPE deposit for-
mation (drusen and soft basal linear deposits) between
the RPE and BM occurs and is also thought to be the
main site of immune complex formation in AMD. While
containing over 40 % lipids, other components of
sub-RPE deposits include TIMP3 (TIMP metallopepti-
dase inhibitor 3), which plays a role in ECM mainten-
ance and remodeling [85, 86]; amyloid beta (Aβ) that
is produced either systemically or from the RPE and
is proangiogenic and a known activator of comple-
ment [87]; apolipoproteins, which are also generated
systemically and by the RPE [88]); and CFH and
other complement components [30].
Lipid accumulation, similar to that seen in atheroscler-
osis, can increase choroidal vessel resistance preventing
the choriocapillaris from properly clearing additional li-
poproteins from the RPE and BM [89]. The accumula-
tion of lipoproteins along with Aβ lead to the formation
of a lipid “wall” external to the RPE [90, 91] that is the
precursor to basal linear deposits that forms between
the RPE basement membrane and the inner collagenous
zone of BM [92]. The accumulated, peroxidizable lipo-
proteins are oxidized contributing to RPE damage [93].
Fig. 2 The alternative complement pathway and the formation of the
C3 convertase. In the AP, the generation of C3b can occur by either
spontaneous hydrolysis of C3 (“tick-over” allowing for continuous low-
level activation) or by plasma proteolytic cleavage all allowing for
immediate C3b deposition. C3b forms the C3 convertase upon binding
to FB and cleavage by FD resulting in an amplification loop producing
additional C3b to stimulate a large immune response. C3b additionally
binds to the C3 convertase leading to the formation of the C5
convertase initiating the terminal pathway and the establishment
of the MAC. This figure was prepared using Servier Medical
Art (http://www.servier.com/Powerpoint-image-bank)
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uct is malondialdehyde (MDA), a marker for oxidative
stress that contributes to RPE dysfunction [94] and a
binding partner to CFH, allowing for an endogenous anti-
inflammatory mediated response to this pro-inflammatory
byproduct [95]. Similar to MDA, another cholesterol ox-
idation product having pro-inflammatory effects is 7-
ketocholesterol (7KCh), which has been associated with
cytotoxicity and has been shown to interact with retinalmicroglia, possibly promoting choroidal neovascularization
[96] [97]. Further, these oxidized low-density lipoproteins
can bind C-reactive protein initiating an inflammatory re-
sponse leading to complement activation [98, 99]. Supple-
menting evidence has also been reported that complement
activation leads to the recruitment of mononuclear phago-
cytes that contribute to RPE pathology in AMD [100]. All
points that support immune system activation as a conse-
quence of pathologic lipid accumulation.
The majority of complement is synthesized primarily
by the liver and is delivered through circulation; how-
ever, some local tissues are also able to synthesize com-
plement components, specifically the RPE and choroid
[55]. Upon factors such as aging, oxidative stress
(including cigarette smoke which that has been reported
in vitro to activate C3 [101]), and lipid accumulation,
increased AP activation in the RPE, which is thought to
be the site of primary dysfunction in AMD, is primed
for genetic predispositions to onset disease progression
[14, 75, 101]. Upon AP activation, initiation of the
terminal pathway ensues, forming MAC in BM and the
choriocapillaris contributing to compromised function
of the tight interaction of the RPE-BM-choroid com-
plex [18].
Additional clues and emerging thoughts on
pathogenic contributions to complex disease
There have been multiple insights implicating comple-
ment components in the pathobiology of AMD including
genetic associations and accumulation of complement
components in sub-RPE deposits of patient retinas [30,
102]. With common variants accounting for 65 % of the
heritability of AMD, the search for rare variant contribu-
tors has only recently been undertaken through the
advances of next generation sequencing [40]. Rare variants
of C3, CFH, CFI, and C9 that have thus far been associ-
ated with AMD have been shown to play a role in either
the complement pathway, to have an impact on the muta-
tional load, or to hold the promise of putative future
therapeutic targets [19, 58, 59, 63, 65]. However, a leading
limitation in understanding disease outcome has been the
lack of comprehension of the functional impact of the
genetic contributors themselves. By combining the com-
mon variant common disease and rare variant common
disease hypotheses [103–105], the idea of mutational bur-
den emerges as a prognostic/diagnostic alternative for
AMD, as exemplified by both common and rare variants
in AP inhibitors leading to pathogenic dysregulated AP ac-
tivity (Table 4). The latter highlights the necessity to func-
tionally assess the role of a variant(s) in a gene(s) in order
to more explicitly understand AMD pathogenesis. This
highlights the need for development of animal models
which are currently in development, for example, a trans-
genic mouse model expressing the human normal (Y402)
Table 4 AP complement variants
Gene Variant Position OR Common/Rare Domain Variant domain effect Effect on AP Ref
C3 R102G 19:6718387 1.7–2.6 Common Macroglobulin 1 Decreased binding efficiency of C3b
to its inhibitor CFH decreasing CFH’s
cofactor activity
Increased AP [20, 65]
C3 P314L 19:6713262 1.5 Common Macroglobulin 3 Decreased binding efficiency of C3b
to its inhibitor CFH decreasing CFH’s
cofactor activity
Increased AP [65]
C3 K155Q 19:6718146 2.8–3.8 Rare Macroglobulin 2 Reduces binding to FH and C3b
proteolytic cleavage by CFI
Increase C3 convertase production [59, 65]
CFB R32Q 6:31914180 0.32 Common Ba Reduced affinity for C3b and
reduced hemolytic activity
Decrease formation of C3 convertase;
reduced AP
[130]
CFB L9H 6:31914024 0.37 Common Signal peptide Affects secretion of CFB Decrease formation of C3 convertase;
reduced AP
[12]
CFH Y402H 1:196659291 2.45–5.57 Common Complement
control protein 7
Affects binding to GAG heparin
sulfate, sialic acid, and C-reactive
protein
Reduces ability of CFH to degrade C3:
increased AP
[131]
CFH R1210C 1:196716375 23.11 Rare Complement
control protein 20
Defective binding to C3b, C3d,
and heparin
Impaired CFH attachment to host
surfaces; reduces AP regulation
[58]
CFH R53C 1:196642206 Rare Complement
control protein 1
Reduced accelerating activity
for AP C3 convertase
Altered CFH-mediated cofactor activity
or decay-accelerating activity; increased AP
[63]
CFH D90G 1:196643011 Rare Complement
control protein 2
Alters CFI cofactor activity Decreased cofactor-mediated inactivation;
increased AP
[63]
CFH I62V 1:196642233 1.95–2.79 Common Complement
control protein 2
Binds more efficiently to C3b Enhanced cofactor activity and increased
formation of iC3b; reduced AP
[63]
CFH N1050Y 1:196712596 0.4 Common Complement
control protein 18
Possibly affects GAG and sialic
acid binding
Increased AP [62]
CFHR1/3 CFHR1/3del 0.29 Common n/a n/a Reduces cofactor activity for CFI and
inhibits C5 convertase; reduced AP
[13] [132–135]
CFI G119R 4:110685820 22.2 Rare Scavenger receptor
cysteine-rich
Perturbs interdomain packing
and stability of CFI
Diminished ability to degrade C3b; increased
formation of C5 convertase; increased AP
[19]
CFI G188A 4:110682768 Rare Scavenger receptor
cysteine-rich
Perturbs interdomain packing
and stability of CFI
Diminished ability to degrade C3b; increased
formation of C5 convertase; increased AP
[19]
C9 P167S 5:39331894 2.2 Rare Membrane attack
complex/perforin
Alters oligomerization and possibly
inhibits C9's lytic activity
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cently been described [106].
Familial aggregation is observed in most complex dis-
ease since there is greater likelihood of sharing disease-
predisposing genotypes; however, non-genetic factors
can contribute to discordant phenotypes [40]. In an ef-
fort to understand disease phenotypic outcomes, most
studies have started by trying to identify causal variants.
The identification of susceptibility variants is hindered
by numerous confounding factors that have to be ac-
knowledged to gain insight into disease mechanism. (1)
Excluding a few cases such as AD and AMD, the vast
majority of common variants exhibit a modest effect
therefore large cohorts are required to power the find-
ings [107, 108]. (2) Rare, disease-causing mutations,
while numerous, are rarely observed in the general
population [60, 83, 109, 110]. (3) SNP association of a
locus does not imply that the causal variant itself is a
SNP, as observed in Crohn’s disease where the causal
mutations is a deletion upstream of the promoter [111].
(4) Multiple distinct alleles either common, rare, or both,
can be present at a single locus [58, 112]. 5) Allele fre-
quencies vary among ethnic groups, as not only ob-
served in AMD but also described in Hirschsprung’s
disease in which the causal variant has a minor allele fre-
quency (MAF) ranging from 0.01 to 0.45 depending on
the population [113]. (6) Causality due to non-coding
variants is difficult to establish, similar to what was ob-
served in coronary artery disease [114–116]. (7) Similar
to pathways functioning in multiple processes, variants
can also be pleiotropic, with their effect being dependent
on the genetic content in which they are identified [117].
8) Genes with causal variants identified need to be fur-
ther studied for additional variation that could contrib-
ute to disease, as was seen in the case when delving
deeper into CFH and CFI in AMD [19, 58]. (9) Struc-
tural variation cannot be ignored, as was observed in the
case of Bardet-Biedl Syndrome in which copy number
variations lead to disease progression (unpublished data).
(10) Environmental factors can modify genetic effects
and phenotypic outcomes [2, 101, 118].
Conclusions
Genetics has aided in the understanding of the complex,
multifactorial nature of AMD. However, with modest
signals differentiating the Dry versus Wet advanced
forms of AMD, genetics has not revealed a strong pre-
dictive value on phenotypic severity or progression. Des-
pite the long road of discovery that lies ahead, various
lines of evidence linking the AP to AMD disease patho-
genesis including (a) clinical phenotypes that associate
with deficiencies of AP regulators [119]; (b) linkage of
SNPs in AP components to disease risk [11, 120]; and
(c) the functional analysis of individual AP componentsin the establishment of clinical phenotypes observed in
both mouse and zebrafish models [74]. With numerous
mouse models recapitulating at least 10 distinct human dis-
orders, such as rheumatoid arthritis, traumatic brain injury,
and AMD, the effects of AP on development and homeo-
stasis have been established, making it clear that dysregula-
tion/dysfunction of the process of innate immunity plays a
contributory role in disease outcome [74]. Predominant
functional assays for measuring the impact of variation on
the complement pathway have been hemolytic and enzyme
immunoassays [59, 121–123]; focus should and has begun
to be placed on additional in vivo model systems to further
understand the roles of AP disease contributors in a more
systemic context [100, 106].
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